LRMR

Larimar Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↓ 2/10
  • Value↓ 4/10
Larimar Therapeutics sales and earnings growth
LRMR Growth
Fair
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ -71.97%
  • FCF Y/Y↓ -58.95%
Larimar Therapeutics gross and profit margin trends
LRMR Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -86.22%
Larimar Therapeutics net debt vs free cash flow
LRMR Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Larimar Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗